Prompt panretinal photocoagulation

OTHER2 trials

Sponsors

Jaeb Center for Health Research, Zhongshan Ophthalmic Center, Sun Yat-sen University

Conditions

Non Proliferative Diabetic RetinopathyProliferative Diabetic Retinopathy

Phase 3

Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy

CompletedNCT01489189

Jaeb Center for Health ResearchProliferative Diabetic Retinopathy

Start: 2012-03-31End: 2018-02-05Updated: 2021-10-29

Unknown Phase

Pars-plana Vitrectomy vs Panretinal Photocoagulation for Severe NPDR

Zhongshan Ophthalmic Center, Sun Yat-sen UniversityNon Proliferative Diabetic Retinopathy

Start: 2019-12-04End: 2025-12-31Target: 272Updated: 2023-03-30

Related Papers

Microinvasive pars plana vitrectomy versus panretinal photocoagulation for severe non-proliferative diabetic retinopathy: a randomised controlled trial

British Journal of Ophthalmology2026-07-17

Baseline Diabetic Retinopathy Severity and Time to Diabetic Macular Edema Resolution with Ranibizumab Treatment: A Meta-Analysis.

2023-02-101 citations

Lapses in Care Among Patients Assigned to Ranibizumab for Proliferative Diabetic Retinopathy

JAMA Ophthalmology2021-10-2129 citations

Microinvasive pars plana vitrectomy versus panretinal photocoagulation in the treatment of severe non-proliferative diabetic retinopathy (the VIP study): study protocol for a randomised controlled trial

BMJ Open2021-02-011 citations

Visual Field Changes Over 5 Years in Patients Treated With Panretinal Photocoagulation or Ranibizumab for Proliferative Diabetic Retinopathy

JAMA Ophthalmology2020-01-3060 citations

Five-Year Cost-effectiveness of Intravitreous Ranibizumab Therapy vs Panretinal Photocoagulation for Treating Proliferative Diabetic Retinopathy

JAMA Ophthalmology2019-10-2454 citations

Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy

JAMA Ophthalmology2018-07-25371 citations

Ranibizumab-Induced Diabetic Retinopathy Improvement—Results from Patients at High Risk for Vision Loss in RIDE/RISE and Protocol S

Diabetes2018-06-221 citations

Ranibizumab in Diabetic Macular Oedema - A Benefit-risk Analysis of Ranibizumab 0.5 mg PRN Versus Laser Treatment.

2017-08-224 citations

Cost-effectiveness of Intravitreous Ranibizumab Compared With Panretinal Photocoagulation for Proliferative Diabetic Retinopathy

JAMA Ophthalmology2017-05-1168 citations

Interim Safety Data Comparing Ranibizumab With Panretinal Photocoagulation Among Participants With Proliferative Diabetic Retinopathy

JAMA Ophthalmology2017-05-1113 citations

Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy

JAMA2015-11-13743 citations